Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress

Rhea-AI Summary

Talaris Therapeutics (TALS) announced significant presentations at the American Transplant Congress from June 4-9, 2021. Key highlights include data from the Phase 2 study of FCR001, emphasizing peripheral blood chimerism's role as a biomarker for transplantation tolerance. Results show a predictive correlation between chimerism levels and the ability to withdraw immunosuppression within one year. In a trial with 37 kidney transplant recipients, 26 achieved durable chimerism, maintaining rejection-free status for up to 12 years. The company will also host invited sessions and poster presentations.

BOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced upcoming presentations of data from the company’s Phase 2 study of FCR001 at the American Transplant Congress taking place virtually June 4-9, 2021.

The accepted oral presentation includes data on the company’s analysis of peripheral blood chimerism as a biomarker for transplantation tolerance. Phase 2 data indicate that one, three, six, and 12-month chimerism levels are highly correlated with each other and increasingly predictive over time of the ability to withdraw immunosuppression at one year, suggesting that whole blood and T-cell chimerism could be a valuable surrogate marker of the ability to discontinue immunosuppression at one year without rejection of the transplanted organ.

In addition, a poster will report on the long-term follow-up of the company’s Phase 2 trial in living donor kidney transplant recipients. Among the 37 subjects administered FCR001, 26 displayed durable chimerism allowing for full withdrawal of immunosuppression, and updated data show that all stable chimeric subjects remain rejection-free with a minimum follow-up of four years and the longest follow-up of almost 12 years.

The company will also be delivering two invited presentations and two sponsored virtual lounge sessions.

INVITED ORAL PRESENTATIONS

Title: “Cellular Therapy to Modify the Recipient Immune System”
Presenter: Suzanne Ildstad, Talaris Therapeutics
Session Title: New Approaches to Tackling Alloimmunity
Date & Time: Friday, June 4, 3:00 p.m. ET

Title: “Peripheral Blood Hematopoietic Chimerism: A Robust Biomarker for Transplantation Tolerance”
Session Title: What’s Hot and What’s New
Date & Time: Wednesday, June 9, 12:25 p.m. ET

ORAL ABSTRACT PRESENTATION

Title: “Peripheral Blood Hematopoietic Chimerism: A Robust Biomarker for Transplantation Tolerance”
Presenter: David Tollerud, Talaris Therapeutics
Session Title: Biomarkers, Immune Assessment and Clinical Outcomes - I
Abstract: 18
Date & Time: Saturday, June 5, 5:05 p.m. ET

POSTER PRESENTATION

Title: “Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients”
Presenter: Joe Leventhal, M.D., Ph.D., Northwestern Memorial Hospital 
Session Title: Tolerance: Clinical Studies
Abstract: 685

SPONSOR CONNECT SESSIONS

Session 1: Sunday, June 6, 11:30 a.m. - 12:00 p.m. ET
Presenter: Suzanne Ildstad, Talaris Therapeutics
Title: FCR001 Investigational Cellular Therapy in Living Donor Kidney Transplantation

Session 2: Monday, June 7, 11:30 a.m. - 12:00 p.m. ET
Presenter: Nancy Krieger, Talaris Therapeutics
Title: FCR001 Investigational Cellular Therapy in Living Donor Kidney Transplantation

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
(339) 970-2843

FAQ

What is Talaris Therapeutics presenting at the American Transplant Congress?

Talaris Therapeutics will present data on their Phase 2 study of FCR001, focusing on peripheral blood chimerism as a biomarker for transplantation tolerance.

What did the Phase 2 study of FCR001 reveal?

The Phase 2 study indicated that chimerism levels are highly predictive of the ability to withdraw immunosuppression without organ rejection.

How many kidney transplant recipients showed durable chimerism in the trial?

Out of 37 kidney transplant recipients in the trial, 26 exhibited durable chimerism that allowed for full withdrawal of immunosuppression.

What are the dates for the American Transplant Congress presentations?

The American Transplant Congress is taking place virtually from June 4-9, 2021.

What sessions will Talaris Therapeutics host during the congress?

Talaris will conduct invited presentations and sponsor two virtual lounge sessions discussing FCR001 and its implications in living donor kidney transplantation.